Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
Stocks · News reference
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.